FDA
-
-
-
-
-
-
-
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
-
-
-
-
-
-
-
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
-
-
-
-
-
-
-
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
-
-
-
-
-
-
-
Takeda (TAK) announces EC approval of ADCETRIS
-
-
-
-
-
-
-
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
-
-
-
-
-
-
-
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
-
-
-
-
-
-
-
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
-
329,907 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

